James Oliviero
Chief Executive Officer chez CHECKPOINT THERAPEUTICS, INC.
Fortune : 928 839 $ au 31/03/2024
Profil
James F.
Oliviero is currently the President, Chief Executive Officer & Director at Checkpoint Therapeutics, Inc. He is also an Independent Director at Nuvectis Pharma, Inc. Previously, he served as the Finance Director at ACCESS Oncology, Inc. from 1999 to 2003.
He then worked as the Chief Financial Officer & Treasurer at Keryx Biopharmaceuticals, Inc. from 2003 to 2015.
Mr. Oliviero completed his undergraduate degree at Goizueta Business School-Emory.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/03/2024 | 341 780 ( 1,50% ) | 700 649 $ | 31/03/2024 | |
NUVECTIS PHARMA, INC.
0,16% | 16/06/2023 | 27 828 ( 0,16% ) | 228 190 $ | 31/03/2024 |
Postes actifs de James Oliviero
| Sociétés | Poste | Début |
|---|---|---|
| CHECKPOINT THERAPEUTICS, INC. | Chief Executive Officer | 13/10/2015 |
| NUVECTIS PHARMA, INC. | Director/Board Member | 01/07/2021 |
Anciens postes connus de James Oliviero
| Sociétés | Poste | Fin |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Director of Finance/CFO | 01/09/2015 |
ACCESS Oncology, Inc.
 ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Director of Finance/CFO | 01/05/2003 |
Formation de James Oliviero
| Goizueta Business School-Emory | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CHECKPOINT THERAPEUTICS, INC. | Health Technology |
| NUVECTIS PHARMA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Health Technology |
